Pengfei Liu

Dr. Pengfei Liu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
PLPengfei Liu
Pengfei Liu
LPLei Pan
Lei Pan
LCLei Cui
Lei Cui
TLTianzuo Li
Tianzuo Li
SZSheng Zhao
Sheng Zhao
XXXinying Xue
Xinying Xue

1 January 2021 in International Journal of Medical Sciences
Verified
Journal Article
Open access
GLGang Li
Gang Li
YYYitian Yang
Yitian Yang
DGDanyang Gao
Danyang Gao
YXYongxing Xu
Yongxing Xu
JGJianwen Gu
Jianwen Gu
PLPengfei Liu
Pengfei Liu
Background: Considering transaminase more than the upper limit of normal value as liver injury might overestimate the prevalence of liver involvement in COVID-19 patients. No meta-analysis has explored the impact of varied definitions of liver injury on the reported prevalence of liver injury. Moreover, few studies reported the extent of hypertransaminasemia stratified by COVID-19 disease severity.

12 November 2020 in BMJ Open
Verified
Journal Article
Open access
SWShaoheng Wang
Shaoheng Wang
QZQing Zhang
Qing Zhang
LCLinfeng Chen
Linfeng Chen
GLGang Liu
Gang Liu
PLPengfei Liu
Pengfei Liu
Introduction: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is a well-established treatment for peritoneal cancer (PC). However, this kind of combination therapy is associated with a high incidence of complications. Moreover, relative studies have indicated that traditional laboratory testing is insufficient to demonstrate the overall haemostatic physiology of CRS/HIPEC. Thromboelastography (TEG), administered by monitoring dynamic changes in haemostasis, has been shown to contribute to reducing transfusion requirements and improving survival. However, there is no evidence to verify whether TEG can be applied to guide transfusion strategies during CRS/HIPEC. Therefore, we aim to investigate whether TEG-guided blood product transfusion (TEG-BT) therapy is superior to traditional blood product transfusion (T-BT) therapy for guiding perioperative blood transfusion treatment and improving the prognosis of patients undergoing CRS/HIPEC.Methods and analysis: The TEG-BT versus T-BT study is a single-centre, randomised, blinded outcome assessment clinical trial of 162 patients with PC, aged 18–64 years and undergoing CRS/HIPEC. Participants will be randomly allocated to receive TEG-BT or T-BT. The primary outcome will be the evaluation of perioperative blood transfusion, which refers to the total amount of blood transfusion given from the time patients enter the operating room up to 72 hours postoperatively. The secondary outcomes will include the transfusion volume during surgery, total amount of intraoperative infusion, amount of blood lost during the operation, total blood transfusion between 0 and 72 hours after surgery, lowest haemoglobin level within 72 hours after surgery, intensive care unit duration, overall length of stay, total cost of hospitalisation and adverse events. Data will be analysed according to the intention-to-treat principle.Ethics and dissemination: The study protocol has been approved by the Scientific Research Ethics Committee of Beijing Shijitan Hospital Affiliated with Capital Medical University (Approval Number: sjtkyll-lx-2020-3). The results will be published in peer-reviewed journals.Trial registration number: Chinese Clinical Trial Registry (ChiCTR2000028835).

7 July 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
GLGang Li
Gang Li
YXYongxing Xu
Yongxing Xu
YYYitian Yang
Yitian Yang
PLPengfei Liu
Pengfei Liu
Introduction: COVID-19 has spread rapidly in China and around the world. Published studies have revealed that some patients with COVID-19 had abnormal liver function in laboratory tests. However, the results were inconsistent and the analysis of epidemiological data stratified by the severity of COVID-19 was not available in previous meta-analyses. Furthermore, these meta-analyses were suspected of overestimating the incidence of liver injury in patients with COVID-19 because some studies considered transaminase elevation as liver injury, which might partially result from cardiac and muscle injury. This systematic review aims to enrol published literatures related to COVID-19 without language restriction, analyse the data based on the severity of the COVID-19 and explore the impact of varied definitions of liver injury on the incidence of liver injury.Methods and analysis: We have conducted a preliminary search on PubMed and Excerpta Medica Database on 13 April 2020, for the studies published after December 2019 on the prevalence of acute liver injury and hypertransaminemia in patients with COVID-19. Two reviewers will independently screen studies, extract data and assess the risk of bias. We will estimate the pooled incidence of hypertransaminemia and acute liver injury in patients with COVID-19 by using the random-effects model. The I² test will be used to identify the extent of heterogeneity. Publication bias will be assessed by funnel plot and performing the Begg’s and Egger’s test if adequate studies are available. We will perform a risk of bias assessment using the Joanna Briggs Institute’s critical appraisal checklist.Ethics and dissemination: Since this study will be based on the published data, it does not require ethical approval. The final results of this study will be published in a peer-reviewed journal.PROSPERO registration number: CRD42020179462.

1 January 2026 in Open Medicine
Verified
Journal Article
Open access
PDF file
YAYifan An
Yifan An
PLPengfei Liu
Pengfei Liu
LLLei Liu
Lei Liu
XHXiaoyun Hu
Xiaoyun Hu
HQHui Qiao
Hui Qiao
WSWeixuan Sheng
Weixuan Sheng
Objectives: To develop and validate machine learning (ML) models for identifying key predictors and estimating the risk of intraoperative hypotension (IOH) in elderly patients undergoing general anesthesia. Methods: This secondary analysis included 1,720 elderly surgical patients from a randomized controlled trial. Data were split chronologically into training sets. Feature selection was performed using univariate analysis and the Boruta algorithm. Eight ML models – logistic regression, Bayesian model, K-nearest neighbor, support vector machine, neural network, classification and regression tree, extreme gradient boosting, and random forest – were developed with cross-validation, hyperparameter tuning, and random oversampling. Model performance was evaluated using ROC, PRC, calibration, and decision curve analyses, and interpretability was enhanced using SHapley Additive exPlanations (SHAP). Results: Key predictors included anesthesia protocol, Charlson comorbidity index, preoperative sodium, creatinine, BUN/creatinine ratio, intraoperative drug use (e.g., sevoflurane, lidocaine, morphine), preoperative MAP and MHR, surgical and anesthesia duration, and surgical site. The random forest model achieved the best performance (accuracy=0.9917; MCC=0.9832; AUC-ROC=0.9998; AUC-PRC=0.9998). Conclusions: A robust ML-based model was established to accurately predict IOH in elderly patients. These findings may support individualized anesthesia management and targeted preventive strategies to reduce IOH incidence.

16 June 2025 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
YTYan Tao
Yan Tao
NCNan Cai
Nan Cai
JZJuxia Zhang
Juxia Zhang
YZYan Zhou
Yan Zhou
PLPengfei Liu
Pengfei Liu
Objective: To investigate the effect of single femoral nerve block (SFNB) with 0.2% ropivacaine 50 ml on postoperative pain and muscle strength in elderly patients undergoing knee replacement.Methods: Ninety-four patients scheduled for primary total knee arthroplasty (TKA) were randomized into two groups. The patients in the SFNB group received SFNB with 50 ml 0.2% ropivacaine (n = 48), while the patients in the continuous femoral nerve block (CFNB) group (n = 46) received CFNB with an initial load of 20 ml 0.5% ropivacaine and a continuous injection of 0.2% ropivacaine at a rate of 5 ml/h. After the surgery, all patients were administered patient-controlled intravenous analgesia. The primary outcome was the visual analogue scale (VAS) score at 24 h postoperatively. The secondary outcomes included: (a) Pain scores at 2 h, 6 h, 12 h, 48 h, and 72 h after surgery, and the total dosage of celecoxib; (b) Muscle strength of the quadriceps at 2 h, 6 h, 12 h, 24 h, 48 h, and 72 h postoperatively; (c) Range of motion (ROM) at 24 h, 72 h, and 1 week after surgery; (d) American Knee Society knee score (AKS) at 1 week postoperatively; (e) Related complications (e.g., nausea and vomiting), and length of hospitalization; (f) General Comfort Questionnaire (GCQ) score at 72 h postoperatively.Results: (a) There were no statistically significant differences in VAS scores (p > 0.05) or the total dosage of celecoxib (p > 0.05) between the two groups at various time points; (b) The muscle strength scores in the SFNB group were higher than those in the CFNB group (p < 0.05) at 6 h, 12 h, and 24 h postoperatively; (c) Knee ROM in the SFNB group was better than in the CFNB group (p < 0.05); (d) There were no significant differences in adverse events between the two groups (p > 0.05); (e) The physiological and psychological scores on the GCQ in the SFNB group were higher than those in the CFNB group (p < 0.05).Conclusion: SFNB, with 0.2% ropivacaine 50 ml provides effective pain relief, and improves patient comfort after surgery, without increasing adverse effects. SFNB is a safe and convenient option for postoperative pain management following knee surgery.